Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients
The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
The serotonin transporter gene promoter polymorphism (5-HTTLPR) has been repeatedly associated with antidepressant response in mood disorder patients, but findings are not consistent across studies. A meta-analysis was performed on 15 studies including data of 1435 subjects. We tested three phenotypes: remission rate, response rate and response rate within 4 weeks using the cochrane review manager. We observed a significant association of the s/s variant of 5-HTTLPR with remission rate (P<0.0001) and both s/s and s/l variants with response rate (P=0.0002). Response rate within 4 weeks was associated in both models (P=0.003-P<0.00001). This effect is quite robust to ethnic differences although a significant heterogeneity is present in Asian samples.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“L-alleles result in greater mRNA transcription and more active 5-HTT function (Parsey et al., 2006) and have been associated with a better treatment response to selective serotonin reuptake inhibitor (SSRI) antidepressants although discrepant findings exist (Serretti et al., 2007).”
From Affective Cognition and its Disruption in Mood Disorders (2011) · cites this paper as Serretti et al., 2007
Citations
Cites
Allelic Variation of Human Serotonin Transporter Gene Expression
Heils, A., Teufel, A., Petri, S., Stöber, G., Riederer, P., Bengel, D., & Lesch, K. P. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66062621.x · Cited by 2,221
Size and burden of mental disorders in Europe—a critical review and appraisal of 27 studies
Wittchen, H.-U., & Jacobi, F. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.04.012 · Cited by 1,503
Diagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380
Hu, X.-Z., Lipsky, R. H., Zhu, G., Akhtar, L. A., Taubman, J., Greenberg, B. D., Xu, K., Arnold, P. D., Richter, M. A., Kennedy, J. L., et al. (2006) · The American Journal of Human Genetics · doi:10.1086/503850 · Cited by 1,123
(1994) · PharmacoResources · doi:10.1007/bf03289581 · Cited by 974
DEFINITION AND EPIDEMIOLOGY OF TREATMENT-RESISTANT DEPRESSION
Fava, M., & Davidson, K. G. (1996) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70283-5 · Cited by 797
Kirchheiner, J., Nickchen, K., Bauer, M., Wong, M.-L., Licinio, J., Roots, I., & Brockmöller, J. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001494 · Cited by 724
Meta-analysis of genetic association studies
Munafò, M. R., & Flint, J. (2004) · Trends in Genetics · doi:10.1016/j.tig.2004.06.014 · Cited by 642
The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants
Nakamura, M., Ueno, S., Sano, A., & Tanabe, H. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000698 · Cited by 633
Smeraldi, E., Zanardi, R., Benedetti, F., Bella, D. D., Perez, J., & Catalano, M. (1998) · Molecular Psychiatry · doi:10.1038/sj.mp.4000425 · Cited by 614
Cited by
Items 301–400 of 535
Pivac, N., Erjavec, G. N., Mustapić, M., Perhoč, A. B., Stipčević, T., Borovečki, F., Hajnšek, S., & Mück‐Šeler, D. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.06.080 · Cited by 14
“to antidepressants [32].”
BackgroundRamasubbu, R., Burgess, A., Gaxiola‐Valdez, I., Cortese, F., Clark, D., Kemp, A., Goodyear, B. G., MacQUEEN, G. M., Bech‐Hansen, N. T., Foster, J. A., et al. (2016) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2521 · Cited by 14
“The reduced transcriptional efficiency for 5-HTT has been proposed as a molecular basis for adverse effects and poor response associated with SSRI treatment in S/Lg carriers (Serretti et al., 2007; Kato and Serretti, 2010).”
BackgroundLe syndrome sérotoninergique : une revue actualisée de la littérature
Jurek, L., Nourredine, M., Mégarbane, B., d’Amato, T., Dorey, J., & Rolland, B. (2018) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2018.08.010 · Cited by 19
Ramesh, V., Venkatesan, V., & Ramasamy, B. (2022) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2830 · Cited by 14
Pharmacogenomics in Practice: A Case Report of Personalized Inpatient Psychiatric Care
Madan, A., Walker, C. R., Weinstein, B. L., & Fowler, J. C. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.9 · Cited by 15
Pharmacogenetics – genomics and personalized psychiatry
Möller, H. ‐., & Rujescu, D. (2010) · European Psychiatry · doi:10.1016/j.eurpsy.2009.12.015 · Cited by 14
“[18] provided a review on the association of antidepressant response with the 5-HTTLPR polymorphism.”
BackgroundStjepanović, D., Lorenzetti, V., Yücel, M., Hawi, Z., & Bellgrove, M. A. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.41 · Cited by 15
“This association between amygdala hyperactivity in s allele carriers has been confirmed by two meta-analyses.(23,24) In addition, Scherk et al.”
Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know?
Seripa, D., Lozupone, M., Stella, E., Paroni, G., Bisceglia, P., Montagna, M. L., D’Onofrio, G., Gravina, C., Urbano, M., Priore, M. G., et al. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1389891 · Cited by 13
“medications, as well as a longer time to response [157].”
BackgroundNasso, E. D., Chiesa, A., Serretti, A., Ronchi, D. D., & Mencacci, C. (2011) · Clinical Drug Investigation · doi:10.2165/11588800-000000000-00000 · Cited by 13
Self-citationKarlović, D., & Karlović, D. (2013) · Acta Clinica Croatica · Cited by 19
Serretti, A., Gibiino, S., & Drago, A. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.08.018 · Cited by 14
Self-citationQin, M., Wu, J., Zhou, Q., Liang, Z., & Su, Y. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.09.039 · Cited by 12
Pharmacogenetics of mood disorders: what clinicians need to know
Laje, G. (2013) · CNS Spectrums · doi:10.1017/s1092852913000278 · Cited by 15
“Studies such as STAR*D have identified clinical variables associated with poorer outcome, such as frequency and severity of concomitant medical illness and/or anxious depression subtype,13 but other comorbidities had already been recognized, for example personality disorders, alcohol abuse, and drug abuse (reviewed in…”
Nonen, S., Kato, M., Takekita, Y., Wakeno, M., Sakai, S., Serretti, A., & Kinoshita, T. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000454 · Cited by 12
“We previously reported that 5-HTT LPR and a functional polymorphism near 5-HTT LPR, rs25531, were associated with interindividual variability of treatment efficacy of SSRIs,(9,10) which was confirmed by meta-analysis.(11) Nevertheless, a single genetic variant may explain approximately 2% to 3% of the variation of com…”
BackgroundSelf-citationAvula, R., Rand, A., Black, J. L., & O’Kane, D. J. (2011) · Translational Psychiatry · doi:10.1038/tp.2011.34 · Cited by 12
“Variations in the promoter region of 5-HTT have been reported to be associated with differential remission rates following selective serotonin reuptake inhibitor medication treatment.(1,2) The long form of the ins/del promoter variant has 43 or 44 more nucleotides than the short form and has been”
BackgroundInfluentialPharmacogenetic studies: a tool to improve antidepressant therapy
Ramos, M., Berrogain, C., Concha, J., Lomba, L., García, C. B., & Ribate, M. P. (2016) · Drug Metabolism and Personalized Therapy · doi:10.1515/dmpt-2016-0019 · Cited by 12
“confirmed the role of 5-HTTLPR in AD response, showing that patients homozygous for the short allele have a slower improvement of depressive and somatic anxiety symptoms [32].”
Towbin, K. E., Solages, M. M., & Stubbe, D. E. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch12 · Cited by 13
Reynolds, K. K., Pierce, D. L., Weitendorf, F., & Linder, M. W. (2017) · Personalized Medicine · doi:10.2217/pme-2016-0095 · Cited by 12
Genetics of antidepressant response and treatment-resistant depression
Chung, A.-N., Chen, T., & Lin, K. (2023) · Progress in brain research · doi:10.1016/bs.pbr.2023.01.002 · Cited by 14
Jaros, A., Rybakowski, F., Cielecka‐Piontek, J., Paczkowska‐Walendowska, M., Czerny, B., Kamiński, A., Elsorady, R. W. M., & Bienert, A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111397 · Cited by 12
Molecular Imaging of Depressive Disorders
Ruhé, H. G., Visser, A. K. D., Frøkjær, V. G., Haarman, B. C. M., Klein, H. C., & Booij, J. (2014) · Springer eBooks · doi:10.1007/978-3-642-40384-2_5 · Cited by 15
Naudts, K. H., Azevedo, R. T., David, A. S., van Heeringen, K., & Gibbs, A. A. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001295 · Cited by 12
Javelle, F., Đào, G. J., Ringleb, M., Pulverer, W., & Bloch, W. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03356-w · Cited by 11
“For example, the promoter region of the 5-HTT gene contains a polymorphism known as the Serotonin Transporter-Linked Polymorphic Region ( 5-HTTLPR ), which has been associated with both depression susceptibility and treatment response [12 – 14].”
Rundell, J. R., Staab, J. P., Shinozaki, G., & McAlpine, D. E. (2011) · Psychosomatics · doi:10.1016/j.psym.2010.12.013 · Cited by 10
“Serretti et al.(16) reported in a meta-analysis a significant association between the s variant of 5-HTTLPR and poorer response to SSRI medications, as well as a longer time to response.”
BackgroundHemispheric specialization for emotional word processing is a function of SSRI responsiveness
Walsh, A. T., McDowall, J., & Grimshaw, G. M. (2010) · Brain and Cognition · doi:10.1016/j.bandc.2010.09.003 · Cited by 11
Using Gene–Environment Interactions to Target Personalized Treatment in Mood Disorder
Klengel, T., & Binder, E. B. (2010) · Personalized Medicine · doi:10.2217/pme.10.73 · Cited by 12
Pharmacogenetic considerations for late life depression therapy
Pitychoutis, P. M., Kokras, N., Sanoudou, D., Dalla, C., & Papadopoulou‐Daifoti, Z. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.794786 · Cited by 11
“The latter may possibly be attributed to a generalized responsiveness of the serotonergic system owing to the enhanced expression/activity of 5-HTT [28].”
BackgroundNeurodevelopmental roles and the serotonin hypothesis of autism spectrum disorder
Daly, E., Tricklebank, M. D., & Wichers, R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813323-1.00002-5 · Cited by 13
The Serotonin Link between Alcohol Use and Affective Disorders.
Ketcherside, A., Matthews, I., & Filbey, F. M. (2013) · PubMed · Cited by 14
Kellner, M. B., Demiralay, C., Muhtz, C., Husemann, J., Koelsch, W., Hiemke, C., Yassouridis, A., & Wiedemann, K. (2008) · Psychiatry Research · doi:10.1016/j.psychres.2008.04.025 · Cited by 10
“In depressed patients a significant association of 5-HTTLPR with SSRI efficacy has been reported in a meta-analysis (Serretti et al., 2007).”
Blambila, L., Sabei, P., Raulino, V. G., & Herkenhoff, M. E. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1773677 · Cited by 9
“The (S) allele is associated with reduced transcription and, consequently, with lower clinical efficacy of SSRIs and a higher incidence of adverse effects, especially in individuals with the S/S genotype (Kato and Serretti, 2010; Serretti et al., 2007).”
Clinical utility of serum biomarkers for major psychiatric disorders
van Beveren, N. J. M., & Hoogendijk, W. J. G. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-387718-5.00014-6 · Cited by 11
Mitchell, N. C., Bowman, M. A., Gould, G. G., Koek, W., & Daws, L. C. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.237305 · Cited by 9
“polymorphism that yields a reduction in SERT expression/ function (Serretti et al., 2007).”
BackgroundInfluentialBrunoni, A. R., & Palm, U. (2019) · Springer eBooks · doi:10.1007/978-3-319-95948-1_15 · Cited by 9
Campbell, K. S. J., Collier, A. C., Irvine, M. A., Brain, U. M., Rurak, D. W., Oberlander, T. F., & Lim, K. I. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.680177 · Cited by 10
“For example, polymorphisms in the serotonin transporter gene promoter (5-HTTLPR) are associated with antidepressant efficacy (114).”
BackgroundAntidepressant‐like effects and basal immobility depend on age and serotonin transporter genotype
Mitchell, N. C., Koek, W., & Daws, L. C. (2015) · Genes Brain & Behavior · doi:10.1111/gbb.12238 · Cited by 10
“For example, SERT blockers can be less effective in individuals carrying low expressing variants of SERT (Serretti et al. 2007) and there is some evidence that tricyclics may be less effective in treating geriatric patients (Kok et al.”
BackgroundLin, P., & Wu, Y. ‐. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s120786 · Cited by 9
“Kotler et al25 (1999) Non-ashkenazi Jewish DsM-iV Patients 186 54 (29) 84 (45) 48 (26) controls 217 53 (24) 114 (53) 50 (23) li et al27 (2002) chinese DsM-iV Patients 106 8 (8) 38 (36) 60 (57) controls 190 17 (9) 60 (32) 113 (59) gerra et al21 (2004) italian caucasians DsM-iV Patients 101 27 (27) 44 (44) 30 (30) contr…”
Pharmakogenetik in der Psychiatrie: eine Standortbestimmung
Genetik, D. D. R. N. U., Müller, D., Brandl, E. J., Degenhardt, F., Domschke, K., Grabe, H. J., Gruber, O., Hebebrand, J., Maier, W., Menke, A., et al. (2018) · Der Nervenarzt · doi:10.1007/s00115-017-0479-8 · Cited by 10
Ferraguti, G., Codazzo, C., Petrella, C., Coccurello, R., Ceccanti, M., & Fiore, M. (2020) · Biomedical Reviews · doi:10.14748/bmr.v31.7707 · Cited by 8
Takahashi, H., Higuchi, H., Sato, K., Kamata, M., Yoshida, K., & Nishimura, K. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s123708 · Cited by 8
Takahashi, H., Yoshida, K., Higuchi, H., Kamata, M., Inoue, K., Suzuki, T., & Ishigooka, J. (2014) · Neuropsychobiology · doi:10.1159/000365517 · Cited by 7
Do we need pharmacogenetics to personalize antidepressant therapy?
Lanni, C., Racchi, M., & Govoni, S. M. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1237-5 · Cited by 9
Birth of the blues: emotional sound processing in infants exposed to prenatal maternal depression
Craig, M., Sethna, V., Gudbrandsen, M., Pariante, C. M., Seneviratne, T., Stoencheva, V., Sethi, A., Catani, M., Brammer, M. J., Murphy, D., et al. (2022) · Psychological Medicine · doi:10.1017/s0033291720002688 · Cited by 9
“Further, it would be beneficial for future studies to fractionate infants based on their genotype as, for example, different allelic variants of the of 5-HTT promoter have been reported to modulate the effects of SSRIs differently (Serretti, Kato, De Ronchi, & Kinoshita, 2007).”
Pettitt, A. (2015) · eNeuro · doi:10.1523/eneuro.0032-14.2015 · Cited by 9
“This disruption in the expression of the 5-HT1A autoreceptor has been associated with decreased SSRI response (Serretti et al., 2004; Suzuki et al., 2004; Arias et al., 2005; Hong et al., 2006) and increased susceptibility to depression in adults directly following a stressful life event (Lemonde…”
Sunada, N., Takekita, Y., Nonen, S., Wakeno, M., Koshikawa, Y., Ogata, H., Kinoshita, T., & Kato, M. (2019) · Neuropsychobiology · doi:10.1159/000500614 · Cited by 8
Self-citationEacret, D., Noreck, J., & Blendy, J. A. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113688 · Cited by 8
Complementary Therapy Use of Cardiovascular Patients
Zencirci, A. D. (2013) · Internal Medicine Open Access · doi:10.4172/2165-8048.1000e113 · Cited by 7
“[5].”
Allen, T. A., Harkness, K. L., Lam, R. W. M., Milev, R. V., Frey, B. N., Müller, D. J., Uher, R., Kennedy, S. H., & Quilty, L. C. (2021) · Personality and Mental Health · doi:10.1002/pmh.1514 · Cited by 7
Genetically encoded sensors for in vivo detection of neurochemicals relevant to depression
Zhao, Y., Wan, J., & Li, Y. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16046 · Cited by 7
Ivanets, N. N., Kinkulkina, M. A., Tikhonova, Y. G., Avdeeva, T. I., Ragimov, A. A., Дашкова, Н. Г., Kuznetsov, O. E., Matveev, A. V., Izyumina, T. A., & Orlov, S. V. (2016) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro20161162146-51 · Cited by 7
“Имеются работы [17, 18], в которых связь 5-HTTLPR с эффективностью СИОЗС, а также других групп антидепрессантов не была установлена.”
Στεφανάτου, Α., Kouris, N. T., & Lekakis, J. P. (2010) · PubMed · Cited by 8
Personalized TMS: role of RNA genotyping
Chan, S. T., & Bota, R. G. (2019) · Mental Illness · doi:10.1108/mij-10-2019-0004 · Cited by 6
Pharmacogenetic/Pharmacogenomic Tests for Treatment Prediction in Depression
Islam, F., Gorbovskaya, I., & Müller, D. J. (2021) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-33-6044-0_13 · Cited by 6
Pharmacogenetics of Antidepressant Response
Serretti, A., Drago, A., & Liebman, M. (2008) · Springer eBooks · doi:10.1007/978-0-387-79251-4_14 · Cited by 6
Self-citationVrshek‐Schallhorn, S., Corneau, G. M., Grillo, A. R., Sapuram, V. R., Plieger, T., & Reuter, M. (2022) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2022.105767 · Cited by 6
Affective Disorders and Gender Differences
de Arrieta, P. P. M., & Arenaza, J. G. (2019) · Springer eBooks · doi:10.1007/978-3-030-15179-9_26 · Cited by 9
Pharmacogenetic Testing in Schizophrenia and Posttraumatic Stress Disorder
Ramey-Hartung, B., El-Mallakh, R. S., & Reynolds, K. K. (2008) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2008.08.004 · Cited by 5
Collins, N. J., Campbell, T. S., Donoghue, K. M., Ghosh, U., Smith, J. N., O’Shea, M. C., Nelson, C. M., Bigham, O. K., & Roth, T. L. (2022) · Molecular Psychology Brain Behavior and Society · doi:10.12688/molpsychol.17482.1 · Cited by 6
“, 2010), whereas others report lower antidepressant efficacy among S homozygotes (Gressier et al., 2009; Serretti et al., 2007), which may further depend on antidepressant type and gender (Gressier et al.”
BackgroundPharmacogenetics and Analgesic Effects of Antidepressants in Chronic Pain Management
Rodieux, F., Piguet, V., Berney, P., Desmeules, J. A., & Besson, M. J. (2015) · Personalized Medicine · doi:10.2217/pme.14.61 · Cited by 5
Pharmacogenomics and Psychiatric Clinical Care
Amato, R. J., Boland, J. R., Myer, N. M., Few, L. R., & Dowd, D. (2017) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20170928-01 · Cited by 6
Potential implications of genomic medicine in general practice
Sullivan, F., Lockhart, P., & Usherwood, T. (2010) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2010.tb03820.x · Cited by 5
Neurobiology of Monoaminergic Neurotransmission and Antidepressants
Lopez-Munoz, F. J., & Álamo, C. (2013) · Springer eBooks · doi:10.1007/978-81-322-0825-9_23 · Cited by 5
Genetik und Gen-Umwelt-Interaktionen bei psychischen Erkrankungen
Maier, W., Giegling, I., & Rujescu, D. (2017) · Springer eBooks · doi:10.1007/978-3-662-49295-6_5 · Cited by 5
Støier, J. F., Jørgensen, T. N., Sparsø, T., Rasmussen, H. B., Kumar, V., Newman, A. H., Blakely, R., Werge, T. M., Gether, U., & Herborg, F. (2023) · medRxiv · doi:10.1101/2023.08.29.23294386 · Cited by 5
“Finally, the impaired remission and slower 15 response rate to SSRIs has been reported for depressive patients that are homozygous 16 for the ‘s’ 5-HTTLPR allele (72), which is again consistent with the treatment17 resistant classification of the index patients we describe.”
ResultAging, Genetic Variations, and Ethnopharmacology
Woods, D. L., Mentes, J. C., Cadogan, M. P., & Phillips, L. R. (2015) · Journal of Transcultural Nursing · doi:10.1177/1043659615606202 · Cited by 4
Rundell, J. R., Harmandayan, M., & Staab, J. P. (2011) · Translational Psychiatry · doi:10.1038/tp.2011.7 · Cited by 4
“The findings from this study, including possible associations between 5-HTTLPR allele category and treatment response, are consistent with findings from other studies.(3,5,7,9,10) On the basis of these potential associations, well-powered prospective studies and other study paradigms are needed to further inform the c…”
ResultThe Need for Vigilance in the Marketing of Genomic Tests in Psychiatry
Klitzman, R. (2015) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000000372 · Cited by 4
“Yet though a particular variant has been found to lower drug response substantially, the sensitivity and specificity of this array are insufficient for clinical use (Zhang et al., 2010; Serretti et al., 2007).”
Prokofieva, M., Karadima, G., Koukia, E., Michou, V., Kyprianidou, C., Papageorgiou, C. V., Alexiadis, E., Constantoulakis, P., & Dikeos, D. G. (2017) · Issues in Mental Health Nursing · doi:10.1080/01612840.2017.1364811 · Cited by 4
An Overview of Machine Learning Applications in Mood Disorders
Topolski, N., Jeong, S. H., & Mwangi, B. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.017 · Cited by 4
Precision medicine in mood disorders
Serretti, A. (2022) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.1 · Cited by 6
“30 Initial findings were interesting, 31 – 35 but after over 20 years, replication has occurred in some samples, while replication has not occurred in other samples, and replication has oc-curred in a few other samples but in the opposite direction of the original results.”
BackgroundSelf-citationKarimi, I., Yakhchalian, N., Fathi, M., & Miraghaee, S. (2022) · Universal Journal of Pharmaceutical Research · doi:10.22270/ujpr.v7i3.779 · Cited by 4
Pharmacogenetics in psychiatry
Lohoff, F. W. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139025997.007 · Cited by 4
Neurochemical and Transmitter Models of Depression
Anisman, H., Matheson, K., & Hayley, S. P. (2008) · Elsevier eBooks · doi:10.1016/b978-0-08-045078-0.00004-6 · Cited by 7
Population frequency and risk factors for depression in Eastern Ukraine
Utevska, O., Gorpynchenko, М. Y., Kolyadko, S. P., Maruta, N., Linskiy, I. V., & Атраментова, Л. А. (2020) · The Journal of V N Karazin Kharkiv National University Series Biology · doi:10.26565/2075-5457-2020-35-7 · Cited by 3
Genetics, Behavioral Intervention, and Human Development
Reiss, D. (2017) · Springer eBooks · doi:10.1007/978-3-319-49227-8_2 · Cited by 3
Uzungil, V., Luza, S., Opazo, C., Mees, I., Li, S., Ang, C., Williamson, N. A., Bush, A. I., Hannan, A. J., & Renoir, T. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109837 · Cited by 3
Molecular Imaging of Depressive Disorders
Ruhé, H. G., Frøkjær, V. G., Haarman, B. C. M., Jacobs, G. E., & Booij, J. (2020) · Springer eBooks · doi:10.1007/978-3-030-57231-0_4 · Cited by 3
Mood Disorders: Brain Imaging and Therapeutic Implications
(2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018 · Cited by 3
Pharmacogenomics in Psychiatric Diseases
Kekić, A. (2023) · Springer eBooks · doi:10.1007/978-3-031-45903-0_9 · Cited by 3
Gonda, X., Fountoulakis, K. Ν., Rihmer, Z., Lászik, A., Akiskal, H. S., & Bagdy, G. (2010) · Annals of General Psychiatry · doi:10.1186/1744-859x-9-21 · Cited by 3
“It has also been suggested and described in several studies that the presence of the s allele not only makes one more likely to possess personality traits which are associated with psychiatric diseases, especially anxiety and affective disorders, but it also makes a less favourable response to SSRI antidepressants mor…”
BackgroundAndreescu, C., & Reynolds, C. F. (2012) · Psiquiatría Biológica · doi:10.1016/j.psiq.2012.07.005 · Cited by 5
Smoller, J. W., Finn, C. T., & Gardner-Schuster, E. E. (2008) · Elsevier eBooks · doi:10.1016/b978-0-323-04743-2.50065-2 · Cited by 3
Biomarker-Based Treatment Selection: A Precision Medicine Approach for Depression
Furman, J. L., & Trivedi, M. H. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813333-0.00029-9 · Cited by 3
Evidence-based pharmacotherapy of major depressive disorder
Dupuy, J. M., Ostacher, M. J., Huffman, J. C., Perlis, R. H., & Nierenberg, A. A. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511910395.005 · Cited by 4
Brunoni, A. R. (2012) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.47.2012.tde-03122012-110639 · Cited by 5
Genetic and epigenetic predictors of antidepressant response
Lyndon, S. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111738 · Cited by 3
The Role of MicroRNAs in Stress-Induced Psychopathologies
Issler, O., & Chen, A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802175-0.00011-5 · Cited by 3
Genetic Factors Underlying Treatment Resistance in Psychiatry
Maron, E., Lan, C., & Nutt, D. J. (2018) · Springer eBooks · doi:10.1007/978-981-10-4358-1_3 · Cited by 2
Genome plasticity and neuropsychiatric disorders
Forero, D. A., Trujillo‐Güiza, M. L., & López‐León, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817819-5.00012-7 · Cited by 3
The Search for Personalized Antidepressant Treatments: What have we Learned and Where are we Going
Serretti, A., & Fabbri, C. (2020) · Pharmacogenomics · doi:10.2217/pgs-2019-0086 · Cited by 2
Self-citationNeuroimaging Studies of Effects of Psychotherapy in Depression
Bauer, I. E., & Meyer, T. D. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.021 · Cited by 2
Canbolat, F., Erinç, D. M. T., Sercan, C., Evrensel, A., Ulucan, K., Aydın, A., & Tarhan, K. N. (2021) · The Journal of Neurobehavioral Sciences · doi:10.4103/jnbs.jnbs_44_20 · Cited by 3
Current methods for predicting therapeutic response in patients with depressive disorders
Алексеевич, Г. С., Ivanova, S. А., & Bokhan, N. A. (2022) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202212202115 · Cited by 2
Pharmacogenomics of antidepressants for major depressive disorder
Martin, J. R., & Lee, K. C. (2012) · Mental Health Clinician · doi:10.9740/mhc.n99712 · Cited by 2
Pharmacogenomics in Psychiatry
Leckband, S. G., Bishop, J. R., & Ellingrod, V. L. (2007) · Journal of Pharmacy Practice · doi:10.1177/0897190007304824 · Cited by 2
“21) compared with the s/s genotype.(11) Additional results associated with this analysis are included in Table 1.”
BackgroundResultDepressive Disorders: Major Depressive Disorder and Persistent Depressive Disorder
MacKinnon, D. F. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch50 · Cited by 3
Developmental Monoamine Signaling Impacts Adult Affective and Aggressive Behaviors
Yu, Q. (2012) · doi:10.7916/d8z60w4b · Cited by 2
Pharmacogenomics Applications in Psychiatric Disorders
Lencz, T., & Malhotra, A. K. (2008) · Methods in pharmacology and toxicology · doi:10.1007/978-1-59745-439-1_17 · Cited by 2
Ivanets, N. N., Kinkulkina, M. A., Tikhonova, Y. G., Avdeeva, T. I., Ragimov, A. A., Дашкова, Н. Г., Kuznetsov, O. E., Matveev, A. V., Izyumina, T. A., & Orlov, S. V. (2017) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-017-0411-5 · Cited by 2
“[17], the antidepressant effect of SSRI developed more slowly in Caucasian patients homozygous for the S allele, while the level of remission was lower.”
Electrophysiological Biomarkers for Mood Disorders
Ramakrishnan, N., Murphy, N., Selvaraj, S., & Cho, R. Y. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.015 · Cited by 2
Metadata
- Authors
- Serretti, A., Kato, M., De Ronchi, D., & Kinoshita, T.
- Affiliations
- University of Bologna (IT)
- Kansai Medical University (JP)
- Corresponding author
- Serretti, A
- Venue
- Molecular Psychiatry
- Published
- 2006-12-05
- Volume
- 12
- Issue
- 3
- Pages
- 247-257
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W1982886582
- Cited by
- 529
- References
- 51
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 9 · 2023: 13 · 2022: 12 · 2021: 44 · 2020: 10 · 2019: 18 · 2018: 22 · 2017: 23 · 2016: 28 · 2015: 29 · 2014: 23 · 2013: 38 · 2012: 39
- FWCI
- 3.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- 5-HTTLPR, serotonin transporter gene, promoter polymorphism, selective serotonin reuptake inhibitors, antidepressant response, depression, remission rate, genetic association, ethnic differences, Asian populations
- MeSH terms
- Adult, Aged, Depressive Disorder, Female, Humans, Male, Middle Aged, Polymorphism, Genetic, Promoter Regions, Genetic, MEDLINE, Selective Serotonin Reuptake Inhibitors, Serotonin Plasma Membrane Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.